A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3398-3413

  Ginzinger, Werner ^a   Mühlgassner, Gerhard ^a   Arion, Vladimir B ^a   Jakupec, Michael A ^a   Roller, Alexander ^a   Galanski, Markus ^a   Reithofer, Michael ^a   Berger, Walter ^b   Keppler, Bernhard K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1H BENZIMIDAZOL 2 YL) 1H QUINOXALIN 2 ONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3 (BENZOXAZOL 2 YL) 1H QUINOXALIN 2 ONE; 3 BENZOTHIAZOL 2 YL 1H QUINOXALIN 2 ONE; BENZIMIDAZOLE; BENZOTHIAZOLE; CYTOTOXIC AGENT; LIGAND; OSMIUM DERIVATIVE; QUINOXALINE DERIVATIVE; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE; COLON CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; ELECTROSPRAY MASS SPECTROMETRY; FINITE ELEMENT ANALYSIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; INFRARED SPECTROSCOPY; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE; OVARY CARCINOMA; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET SPECTROSCOPY; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; BENZOTHIAZOLES; BENZOXAZOLES; CELL CYCLE; CELL LINE, TUMOR; COORDINATION COMPLEXES; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OSMIUM; QUINOXALINES; RUTHENIUM; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859805295     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3000906     Document Type: Article

References (65)

1. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. Antitumor metal compounds: more than theme and variations Dalton Trans. 2008, 183-194
2. Reedijk, J. Medicinal applications of metal complexes binding to biological macromolecules Macromol. Symp. 2008, 270, 193-201
3. Fricker, S. P. Metal based drugs: from serendipity to design Dalton Trans. 2007, 4903-4917
4. Clarke, M. J. Ruthenium metallopharmaceuticals Coord. Chem. Rev. 2003, 236, 209-233
5. Bratsos, I.; Jedner, S.; Gianferrara, T.; Alessio, E. Ruthenium Anticancer Compounds: Challenges and Expectations Chimia 2007, 61, 692-697
6. Rademaker-Lakhai, J. M.; Van Den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. M. A Phase I and Pharmacological Study with Imidazolium- trans -DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent Clin. Cancer Res. 2004, 10, 3717-3727
7. Lentz, F.; Drescher, A.; Lindauer, A.; Henke, M.; Hilger, R. A.; Hartinger, C. G.; Scheulen, M. E.; Dittrich, C.; Keppler, B. K.; Jaehde, U. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study Anti-Cancer Drugs 2009, 20, 97-103
8. Gianferrara, T.; Bratsos, I.; Alessio, E. A categorization of metal anticancer compounds based on their mode of action Dalton Trans. 2009, 7588-7598
9. Peacock, A. F. A.; Sadler, P. J. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents Chem. Asian J. 2008, 3, 1890-1899
10. Suess-Fink, G. Arene ruthenium complexes as anticancer agents Dalton Trans. 2010, 39, 1673-1688
11. Liu, H. K.; Berners-Price, S. J.; Wang, F.; Parkinson, J. A.; Xu, J.; Bella, J.; Sadler, P. J. Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex Angew. Chem., Int. Ed. 2006, 45, 8153-8156
12. Wang, F.; Habtemariam, A.; van der Geer, E. P. L; Fernandez, R.; Melchart, M.; Deeth, R. J.; Aird, R.; Guichard, S.; Fabbiani, F. P. A; Lozano-Casal, P.; Oswald, I. D. H.; Jodrell, D. I.; Parsons, S.; Sadler, P. J. Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18269-18274
13. Habtemariam, A.; Melchart, M.; Fernandez, R.; Parsons, S.; Oswald, I. D. H.; Parkin, A.; Fabbiani, F. P. A; Davidson, J. E.; Dawson, A.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J. Structure-Activity Relationships for Cytotoxic Ruthenium(II) Arene Complexes Containing N, N -, N, O -, and O, O -Chelating Ligands J. Med. Chem. 2006, 49, 6858-6868
14. Dyson, P. J. Systematic design of a targeted organometallic antitumor drug in preclinical development Chimia 2007, 61, 698-703
15. Scolaro, C.; Chaplin, A. B.; Hartinger, C. G.; Bergamo, A.; Cocchietto, M.; Keppler, B. K.; Sava, G.; Dyson, P. J. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy Dalton Trans. 2007, 5065-5072
16. Ang, W. H.; Daldini, E.; Scolaro, C.; Scopelliti, R.; Juillerat-Jeannerat, L.; Dyson, P. J. Development of Organometallic Ruthenium-Arene Anticancer Drugs That Resist Hydrolysis Inorg. Chem. 2006, 45, 9006-9013
17. Pawson, T.; Kofler, M. Kinome signaling through regulated protein-protein interactions in normal and cancer cells Curr. Opin. Cell Biol. 2009, 21, 147-153
18. Grant, S. K. Therapeutic Protein Kinase Inhibitors Cell. Mol. Life Sci. 2009, 66, 1163-1177
19. Noble, M. E.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure Science 2004, 303, 1800-1805
20. Bregman, H.; Williams, D. S.; Atilla, G. E.; Carroll, P. J.; Meggers, E. An Organometallic Inhibitor for Glycogen Synthase Kinase 3 J. Am. Chem. Soc. 2004, 126, 13594-13595
21. Maksimoska, J.; Feng, L.; Harms, K.; Yi, C.; Kissil, J.; Marmorstein, R.; Meggers, E. Targeting Large Kinase Active Site with Rigid, Bulky Octahedral Ruthenium Complexes J. Am. Chem. Soc. 2008, 130, 15764-15765
22. Atilla-Gokcumen, G. E.; Pagano, N.; Streu, C.; Maksimoska, J.; Filippakopoulos, P.; Knapp, S.; Meggers, E. Extremely Tight Binding of a Ruthenium Complex to Glycogen Synthase Kinase 3 ChemBioChem 2008, 9, 2933-2936
23. Meggers, E. Targeting proteins with metal complexes Chem. Commun. 2009, 1001-1010
24. Bikker, J. A.; Brooijmans, N.; Wissner, A.; Mansour, T. S. Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies J. Med. Chem. 2009, 52, 1493-1509
25. Hoessel, R.; Leclerc, S.; Endicott, J. A.; Noble, M. E. M.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases Nature Cell Biol. 1999, 1, 60-67
26. Eisenbrand, G.; Hippe, F.; Jakobs, S.; Muehlbeyer, S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine J. Cancer Res. Clin. Oncol. 2004, 130, 627-635
27. Nam, S.; Buettner, R.; Turkson, J.; Kim, D.; Cheng, J. Q.; Muehlbeyer, S.; Hippe, F.; Vatter, S.; Merz, K.; Eisenbrand, G.; Jove, R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 5998-6003
28. Lee, M. J.; Kim, M. Y.; Mo, J. S.; Ann, E. J.; Seo, M.-S.; Hong, J.-A.; Kim, Y.-C.; Park, H. S. Indirubin-3′-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling Cancer Lett. 2008, 265, 215-225
29. Beauchard, A.; Ferandin, Y.; Frere, S.; Lozach, O.; Blairvacq, M.; Meijer, L.; Thiery, V.; Besson, T. Synthesis of novel 5-substituted indirubins as protein kinases inhibitors Bioorg. Med. Chem. 2006, 14, 6434-6443
30. Jautelat, R.; Brumby, T.; Schaefer, M.; Briem, H.; Eisenbrand, G.; Schwahn, S.; Krueger, M.; Luecking, U.; Prien, O.; Siemeister, G. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors ChemBioChem 2005, 6, 531-540
31. Knockaert, M.; Blondel, M.; Bach, S.; Leost, M.; Elbi, C.; Hager, G. L.; Nagy, S. R.; Han, D.; Denison, M.; Ffrench, M.; Ryan, X. P.; Magiatis, P.; Polychronopoulos, P.; Greengard, P.; Skaltsounis, L.; Meijer, L. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins Oncogene 2004, 23, 4400-4412
32. Siemeister, G.; Thierauch, K. H.; Prien, O.; Jautelat, R.; Eisenbrand, G. Therapeutic use of selective indirubin derivatives as VEGF receptor inhibitors. Int. PatentWO 02/092079 A1, November 21, 2002.
33. Davies, T. G.; Tunnah, P.; Meijer, L.; Marko, D.; Eisenbrand, G.; Endicott, J. A.; Noble, M. E. M. Inhibitor Binding to Active and Inactive CDK2 The Crystal Structure of CDK2-Cyclin A/ Indirubin-5-Sulphonate Structure 2001, 9, 389-397
34. Renhowe, P.; Pecchi, S.; Machajewski, T.; Shafer, C.; Taylor, C.; McCrea, B.; McBride, C.; Jazan, E.; Wernette-Hammond, M. E.; Harris, A. Quinolinone Derivatives as Tyrosine Kinase Inhibitors. Int. Patent WO 02/22598 A1, March 21, 2002.
35. Frazier, K.; Jazan, E.; McBride, C. M.; Pecchi, S.; Renhowe, P. A.; Shafer, C. M.; Taylor, C.; Bussiere, D.; Min, He M.; Jansen, J. M.; Lapointe, G.; Ma, S.; Vora, J.; Wiesmann, M. Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases Bioorg. Med. Chem. Lett. 2006, 16, 2247-2251
36. Renhowe, P. A.; Pecchi, S.; Shafer, C. M.; Machajewski, T. D.; Jazan, E. M.; Taylor, C.; Antonios-McCrea, W.; McBride, C. M.; Frazier, K.; Wiesmann, M.; Lapointe, G. R.; Feucht, P. H.; Warne, R. L.; Heise, C. C.; Menezes, D.; Aardalen, K.; Ye, H.; He, M.; Le, V.; Vora, J.; Jansen, J. M.; Wernette-Hammond, M. E.; Harris, A. L. Design, Structure-Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors J. Med. Chem. 2009, 52, 278-292
37. Ladouceur, G. H.; Bear, B.; Bi, C.; Brittelli, D. R.; Burke, M. J.; Chen, G.; Cook, J.; Dumas, J.; Sibley, R.; Turner, M. R. Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis. Int. Patent WO 2004/043950 A1, May 27, 2004.
38. Aoki, K.; Koseki, J.; Takeda, S.; Aburada, M.; Miyamoto, K. Convenient synthetic method for 3-(3-substituted indol-2-yl)quinoxalin-2-ones as VEGF inhibitor Chem. Pharm. Bull. 2007, 55, 922-925
39. Westphal, G.; Scheybal, A.; Lipke, B.; Weber, F. G. Reactions with pyridinium pyruvates Pharmazie 1976, 31, 770-773
40. Westphal, G.; Scheybal, A.; Lipke, B.; Weber, F. G. Preparation of several 3-hetaryl-2-quinoxalinones Pharmazie 1977, 32, 563-565
41. Klicnar, J.; Hajek, M.; Dobas, I. Quinoxaline series. III. Synthesis, reactions, and infrared spectra of some 3-hydroxy-2-carboxymethylquinoxaline derivatives Collect. Czech. Chem. Commun. 1965, 30, 3092-3101
42. Kandioller, W.; Hartinger, C. G.; Nazarov, A. A.; Kasser, J.; John, R.; Jakupec, M. A.; Arion, V. B.; Dyson, P. J.; Keppler, B. K. Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety J. Organomet. Chem. 2009, 694, 922-929
43. Kandioller, W.; Hartinger, C. G.; Nazarov, A. A.; Kuznetsov, M. L.; John, R. O.; Bartel, C.; Jakupec, M. A.; Arion, V. B.; Keppler, B. K. From Pyrone to Thiopyrone Ligands-Rendering Maltol-Derived Ruthenium(II)-Arene Complexes That Are Anticancer Active in Vitro Organometallics 2009, 28, 4249-4251
44. Canivet, J.; Karmazin-Brelot, L.; Suess-Fink, G. Cationic arene ruthenium complexes containing chelating 1,10-phenanthroline ligands J. Organomet. Chem. 2005, 690, 3202-3211
45. Wang, F.; Chen, H.; Parsons, S.; Oswald, I. D. H.; Davidson, J. E.; Sadler, P. J. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts Chem.-Eur. J. 2003, 9, 5810-5820
46. Peacock, A. F. A.; Habtemariam, A.; Fernandez, R.; Walland, V.; Fabbiani, F. P. A; Parsons, S.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J. Tuning the Reactivity of Osmium(II) and Ruthenium(II) Arene Complexes under Physiological Conditions J. Am. Chem. Soc. 2006, 128, 1739-1748
47. Santra, S.; Dogra, S. K. Solvatochromism and prototropic reactions of 2-quinoxalinone Chem. Phys. 1996, 207, 103-113
48. Dadci, L.; Elias, H.; Frey, U.; Hoernig, A.; Koelle, U.; Merbach, A. E.; Paulus, H.; Schneider, J. S. π-Arene Aqua Complexes of Cobalt, Rhodium, Iridium, and Ruthenium: Preparation, Structure, and Kinetics of Water Exchange and Water Substitution Inorg. Chem. 1995, 34, 306-315
49. Peacock, A. F. A.; Habtemariam, A.; Moggach, S. A.; Prescimone, A.; Parsons, S.; Sadler, P. J. Chloro half-sandwich osmium(II) complexes: influence of chelated N, N -ligands on hydrolysis, guanine binding, and cytotoxicity Inorg. Chem. 2007, 46, 4049-4059
50. Damiens, E.; Baratte, B.; Marie, D.; Eisenbrand, G.; Meijer, L. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest Oncogene 2001, 20, 3786-3797
51. Ginzinger, W.; Egger, A.; Mühlgassner, G.; Arion, V. B.; Jakupec, M. A.; Galanski, M.; Berger, W.; Keppler, B. K. Water soluble indirubin derivatives with a quaternary ammonium moiety. Manuscript in preparation.
52. Bennett, M. A.; Smith, A. K. Arene ruthenium(II) complexes formed by dehydrogenation by cyclohexadienes with ruthenium(III) trichloride J. Chem. Soc., Dalton Trans. 1974, 233-241
53. 2] at 203 K Polyhedron 2004, 23, 2695-2707
54. 2 J. Organomet. Chem. 1990, 383, 481-496
55. Brauer, G.; Fehlhammer, W. P.; Glemser, O.; Grube, H. J.; Gustav, K.; Herrmann, W. A.; Herzog, S.; Lux, H.; Müller, H.; Ofele, K.; Schill, E.; Scholdert, R.; Schwärzt, H.; Schwarzmann, E.; Schwochau, K.; Simon, A.; Strähle, J. In Handbuch der Präparativen Anorganischen Chemie, 3rd ed.; Brauer, G., Ed.; Ferdinand Enke Verlag: Stuttgart, 1981; Vol. 3, p 1743.
56. Pressprich, M. R.; Chambers, J. SAINT-Plus Integration Engine, Program for Crystal Structure Integration; Bruker AXS Inc.: Madison, WI, 2004.
57. Sheldrick, G. M. SHELXS-97, Program for Crystal Structure Solution; University Göttingen: Göttingen, 1997.
58. Farrugia, L. J. WinGX suite for small-molecule single-crystal crystallography J. Appl. Crystallogr. 1999, 32, 837-838
59. Sheldrick, G. M. SHELXL-97, Program for Crystal Structure Refinement; University Göttingen: Göttingen, 1997.
60. Spek, A. L. Single-crystal structure validation with the program PLATON J. Appl. Crystallogr. 2003, 36, 7-13
61. Bruker, A. XP -Interactive Molecular Graphics, version 5.1; Bruker AXS Inc.: Madison, WI, 1998.
62. International Tables for X-ray Crystallography; Kluwer Academic Press: Dodrecht, The Netherlands, 1992; Vol. C, Tables 4.2.6.8 and 6.1.1.4.
63. Mosmann, T. J. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983, 65, 55-63
64. Aubry, J.-P.; Blaecke, A.; Lecoanet-Henchoz, S.; Jeannin, P.; Herbault, N.; Caron, G.; Moine, V.; Bonnefoy, J.-Y. Cytometry 1999, 37, 197-204
65. Eller, G. A.; Datterl, B.; Holzer, W. Pyrazolo[4′,3′:5,6] pyrano[2,3- b ]quinoxalin-4(1 H)-one: synthesis and characterization of a novel tetracyclic ring system J. Heterocycl. Chem. 2007, 44, 1139-1143